Ligand Director Disposes $91,490 in Shares; Sale Executed Under 10b5-1 Plan
John W. Kozarich, a director at Ligand Pharmaceuticals, sold 467 shares of the company on February 2, 2026, in transactions totaling $91,490. The trades were made under a pre-established Rule 10b5-1 plan adopted March 7, 2025. Ligand recently reported robust third-quarter revenue of $115.5 million, driven in part by $53.1 million from the Pelthos t…